1
|
Militello L, Zhang V. Performance Evaluation of Two FDA-Approved Fentanyl Immunoassays against LC-MS/MS. Am J Clin Pathol 2022. [DOI: 10.1093/ajcp/aqac126.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Abstract
Introduction/Objective
The increased number of deaths caused by Fentanyl in recent years created the need for accurate, automated assays for fentanyl detection. Many products have been brought to market but there is concern over the sensitivity and specificity of the available immunoassays. Here we evaluate the performance of our current assay, the ARK Fentanyl II Assay (ARK), against the newly FDA-approved Fentanyl Immunoassay for Roche Cobas (Roche), using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the gold standard. To our knowledge, this is the first study to evaluate the performance of the Roche fentanyl immunoassay.
Methods/Case Report
We collected discarded patient urine samples screened for fentanyl using ARK over 3 months to get a total of 100 positive and 100 negative results. All samples were stored at -20 °C and later tested again using ARK, Roche and in-house LC-MS/MS assays. Both immunoassays were performed on Roche Cobas c501 chemistry analyzer. In-house LC-MS/MS assay gave quantitative measurements for both fentanyl and norfentanyl with a limit of quantification of 1 ng/mL for both. Samples with results above 1 ng/mL of either analyte were considered positive for the presence of fentanyl. The upper limit of quantification of the LC-MS/MS assay was 2000 ng/mL. The results obtained from LC-MS/MS were considered as reference values to determine the sensitivity and specificity of the immunoassays, which were calculated by dividing the number of positive and negative samples correctly identified by immunoassay by total positive and negative samples based on LC-MS/MS results, respectively. ARK is designed to detect fentanyl with a cutoff of 1 ng/mL. Roche is designed to detect norfentanyl with a cutoff of 5 ng/mL.
Results (if a Case Study enter NA)
Analytical sensitivity and specificity were 91.9% and 99.3% for ARK and 96.8 and 98.6% for Roche. Fentanyl and norfentanyl levels by LC-MS/MS ranged from <1 to >2000 ng/mL with a mean of 57 and 232 and standard deviation of 235 and 578, respectively. False positives were seen in 1 sample for ARK and 2 samples for Roche. False negatives were seen in 5 samples for ARK and 2 samples for Roche. Roche accurately identified 6 positive samples that had norfentanyl concentrations less than the cutoff of 5 ng/mL, indicating a potential greater sensitivity than stated.
Conclusion
Both immunoassays performed reasonably well, showing great specificity. Roche displayed greater sensitivity.
Collapse
Affiliation(s)
- L Militello
- Pathology, University of Rochester , Rochester, New York , United States
| | - V Zhang
- Pathology, University of Rochester , Rochester, New York , United States
| |
Collapse
|
2
|
Pizzichetta MA, Canzonieri V, Militello L, Borsatti E, Lo Re G, Bolzonello S, Olivieri M, Pinzani C, Magaton-Rizzi G, Puglisi F, Zalaudek I. Dermoscopic features of a primary scalp melanoma and its cutaneous metastases. Ital J Dermatol Venerol 2020; 156:499-501. [PMID: 33228336 DOI: 10.23736/s2784-8671.20.06742-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Maria A Pizzichetta
- Clinic of Dermatology, University of Trieste, Trieste, Italy - .,Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy -
| | - Vincenzo Canzonieri
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.,Division of Pathology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Loredana Militello
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Eugenio Borsatti
- Division of Nuclear Medicine, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Giovanni Lo Re
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Silvia Bolzonello
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Matteo Olivieri
- Division of Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Caterina Pinzani
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | | | - Fabio Puglisi
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy.,Department of Medicine (DAME), University of Udine, Udine, Italy
| | - Iris Zalaudek
- Clinic of Dermatology, University of Trieste, Trieste, Italy
| |
Collapse
|
3
|
Pizzichetta MA, Canzonieri V, Militello L, Borsatti E, Lo Re G, Bolzonello S, Olivieri M, Pinzani C, Magaton-Rizzi G, Puglisi F, Zalaudek I. Dermoscopic features of a primary scalp melanoma and its cutaneous metastases. G Ital Dermatol Venereol 2020. [PMID: 33228336 DOI: 10.23736/s0392-0488.20.06742-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Maria A Pizzichetta
- Dermatologic Clinic, University of Trieste, Trieste, Italy - .,Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy -
| | - Vincenzo Canzonieri
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.,Division of Pathology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Loredana Militello
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Eugenio Borsatti
- Division of Nuclear Medicine, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Giovanni Lo Re
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Silvia Bolzonello
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Matteo Olivieri
- Division of Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Caterina Pinzani
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | | | - Fabio Puglisi
- Department of Medicine (DAME), University of Udine, Italy.,Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
| | - Iris Zalaudek
- Dermatologic Clinic, University of Trieste, Trieste, Italy
| |
Collapse
|
4
|
Militello L, Barrera AMG, Kuerer H, Albarracin C, Arun BK. Abstract P6-08-06: Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for hereditary breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-08-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Multigene panel testing (MPG) for hereditary breast cancer has recently increased significantly. While clinical and pathological characteristics for invasive breast cancer in patients with non BRCA germline mutations is emerging, there is very limited data in patients with ductal carcinoma in situ (DCIS). This study evaluates the clinical and pathological characteristics of patients with DCIS who underwent MPG testing for hereditary breast cancer.
Methods: Patients with DCIS who underwent MPG testing between 2014-2019 were identified from our prospectively maintained and IRB-approved research registry study and included in this analysis. Clinical and tumor characteristics were analyzed using descriptive statistics. Variables included in the analysis included: Age at diagnosis, family history of breast and ovarian cancer, tumor characteristics including ER/PR and nuclear grade and genetic testing results.
Results: In this prospective cohort, 324 patients with DCIS underwent multigene panel testing. Age of diagnosis was 50.5 years (range: 18-86), a family history of breast and/or ovarian cancer was positive in 283 (87.3%) patients. Genetic testing results were as follows: Pathogenic or likely pathogenic mutations were found in 28 (8.6%) patients: BRCA1 2 (7.1%), BRCA2 6 (21.4%), PALB2 6 (21.4%), CHEK2 5 (17.9%), ATM 3 (10.7%), APC 2 (7.1%), BARD1 1 (3.6%), BRIP1 1 (3.6%), MSH2 1 (3.6%), MUTYH 1 (3.6%). The variant of uncertain significance rate was 16% (52): 7 (13.5%) in BRCA1 or 2 and 45 (86.5%) in other genes. 244 (75.3%) of patients had negative results.
Conclusion: Our data demonstrates that, in addition to BRCA 1 and 2 genes, patients with DCIS have other hereditary genes involved. In fact, 71.4% of the germline mutations were in non-BRCA genes. Regardless of gene status, most patients had ER positive disease, this can have implications for chemopreventive therapy. Furthermore, patients with germline mutations have a higher percentage of nuclear grade III DCIS than gene negative patients. Larger studies are needed to evaluate the clinical implications of these findings. Genetic testing with a larger panel, other than BRCA1 and BRCA2 genes only, should be considered for patients with DCIS.
NegativeBRCA1+BRCA2+PALB2+CHEK2+ATM+Variablesn%n%n%n%n%n%ERpositive17471.32100.0583.3350.0480.03100.0negative187.400.000.0116.7120.000.0unknown5120.900.0116.7233.300.000.0PRpositive15262.3150.0583.3350.0480.03100.0negative3815.6150.000.0116.7120.000.0unknown5422.100.0116.7233.300.000.0NGI187.4150.000.000.0240.000.0II10041.000.0116.7350.0240.0133.3III8534.8150.0466.7233.300.0266.7unknown4116.800.0116.7116.7120.000.0Totals244100.02100.06100.06100.05100.03100.0
Citation Format: Loredana Militello, Angelica M Gutierrez Barrera, Henry Kuerer, Constance Albarracin, Banu K Arun. Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for hereditary breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-06.
Collapse
Affiliation(s)
| | | | - Henry Kuerer
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Banu K Arun
- University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
5
|
Militello L, Barrera AMG, Albarracin C, Bedrosian I, Arun BK. Abstract P6-08-26: Clinical characteristics of breast cancer patients with ATM mutations. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-08-26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pathogenic ATM gene mutations are associated with increased risk of developing several cancers such as lymphoid, gastric, breast, central nervous system, skin, and other cancers. The relative risk of breast cancer is 2.3, with a higher risk seen for women under the age of 50 years. Only few and small studies have reported on the characteristics of breast cancers in women with ATM mutations. Here, we aimed to describe the clinical and pathological characteristics of a single institution largest cohort, to the best of our knowledge, of breast cancer patients with ATM mutations.
Methods: Patients with breast cancer who presented to the University of Texas MD Anderson Cancer Center Clinical Cancer Genetics clinics and underwent genetic testing for hereditary breast cancer and were found to have an ATM mutation were included. A retrospective review of a prospectively maintained research database was performed for ATM mutation status as well as patient clinical and pathological characteristics. IRB approval was granted for this analysis.
Results: Between 2012 and 2019, a total of 4093 breast cancer patients underwent genetic testing for hereditary breast cancer that included ATM gene testing. The median age of diagnosis of breast cancer was 49.3 (17-89), and median age at genetic testing was 52.1 (18-86). 72% of patients had stage 0-III and 3.2% stage 4 disease. Among patients with ATM pathogenic mutations, 37.7% (10) versus 21.7% (843) of ATM negative patients had a history of multiple primaries of any cancers. The table below shows characteristics of ATM pathogenic mutation carriers versus ATM negative patients.
Conclusion: This is a single institution cohort of breast cancer patients with ATM mutations that show distinct clinical characteristics, such as multiple primary cancers. These findings could have therapeutic implications and should be confirmed in larger cohorts.
Pathogenic Mutation of ATM ATM NegativesVariablesn%n%ERPositive4075.5221757.1Negative11.976019.6Unknown1222.690423.3PRPositive3667.9188448.5Negative59.4107027.6Pos/Neg00.010.03Unknown1222.692623.9Her2Positive1018.958611.3Negative2241.5206257.0Unknown2139.6123314.2Stage059.43178.2I1324.597825.2II1120.8106527.4III713.243611.2IV47.51243.2Unknown1324.596124.8Nuclear GradeI23.82596.7II1935.8111228.7III1120.8115629.8Unknown2139.6135434.9Triple Negative?Yes00.053913.9No3769.8222757.4Unknown1630.2111528.7
Citation Format: Loredana Militello, Angelica M Gutierrez Barrera, Constance Albarracin, Isabelle Bedrosian, Banu K Arun. Clinical characteristics of breast cancer patients with ATM mutations [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-26.
Collapse
Affiliation(s)
| | | | | | | | - Banu K Arun
- University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
6
|
Vinante L, Avanzo M, Furlan C, Fiorica F, Perin T, Militello L, Spazzapan S, Berretta M, Jena R, Stancanello J, Piccoli E, Mileto M, Micheli E, Roncadin M, Massarut S, Trovò M. Ten daily fractions for partial breast irradiation. Long-term results of a prospective phase II trial. Breast J 2019; 25:243-249. [PMID: 30714257 DOI: 10.1111/tbj.13195] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 03/14/2018] [Accepted: 03/16/2018] [Indexed: 11/30/2022]
Abstract
Partial breast irradiation (PBI) is an effective adjuvant treatment after breast conservative surgery for selected early-stage breast cancer patients. However, the best fractionation scheme is not well defined. Hereby, we report the 5-year clinical outcome and toxicity of a phase II prospective study of a novel regimen to deliver PBI, which consists in 40 Gy delivered in 10 daily fractions. Patients with early-stage (pT1-pT2, pN0-pN1a, M0) invasive breast cancer were enrolled after conservative surgery. The minimum age at diagnosis was 60 years old. PBI was delivered with 3D-conformal radiotherapy technique with a total dose of 40 Gy, fractionated in 10 daily fractions (4 Gy/fraction). Eighty patients were enrolled. The median follow-up was 67 months. Five-year local control (LC), disease-free survival (DFS), and overall survival (OS) were 95%, 91%, and 96%, respectively. Grade I and II subcutaneous fibrosis were documented in 23% and 5% of cases. No grade III late toxicity was observed. PBI delivered in 40 Gy in 10 daily fractions provided good clinical results and was a valid radiotherapy option for early-stage breast cancer patients.
Collapse
Affiliation(s)
- Lorenzo Vinante
- Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Michele Avanzo
- Division of Medical Physics, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Carlo Furlan
- Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.,Department of Radiation Oncology, Belluno General Hospital, Belluno, Italy
| | - Francesco Fiorica
- Department of Radiation Oncology, University Hospital S. Anna, Ferrara, Italy
| | - Tiziana Perin
- Department of Pathology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Loredana Militello
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Simon Spazzapan
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Massimiliano Berretta
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Rajesh Jena
- Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | | | - Erica Piccoli
- Breast Surgery Unit, Department of Oncology and Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Mario Mileto
- Breast Surgery Unit, Department of Oncology and Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Elvia Micheli
- Department of General Surgery, Pordenone General Hospital, Pordenone, Italy
| | - Mario Roncadin
- Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Samuele Massarut
- Breast Surgery Unit, Department of Oncology and Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
| | - Marco Trovò
- Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.,Department of Radiation Oncology, Udine General Hospital, Udine, Italy
| |
Collapse
|
7
|
Dall'Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G, Califano D, Bagnoli M, Militello L, Mezzanzanica D, Chiappetta G, Armenia J, Belletti B, Schiappacassi M, Baldassarre G. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med 2018; 9:1415-1433. [PMID: 28778953 PMCID: PMC5623833 DOI: 10.15252/emmm.201607012] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum‐based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro, in xenografts in vivo, and in primary tumor cells derived from platinum‐treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.
Collapse
Affiliation(s)
- Alessandra Dall'Acqua
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Maura Sonego
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Ilenia Pellizzari
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Ilenia Pellarin
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Vincenzo Canzonieri
- Division of Pathology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Sara D'Andrea
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Sara Benevol
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Roberto Sorio
- Division of Medical Oncology C, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Giorgio Giorda
- Division of Gynecology-Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Daniela Califano
- Genomica Funzionale, Istituto Nazionale Tumori -IRCCS- Fondazione G Pascale, Naples, Italy
| | - Marina Bagnoli
- Molecular Therapies Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy
| | - Loredana Militello
- Division of Medical Oncology C, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Delia Mezzanzanica
- Molecular Therapies Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy
| | - Gennaro Chiappetta
- Genomica Funzionale, Istituto Nazionale Tumori -IRCCS- Fondazione G Pascale, Naples, Italy
| | - Joshua Armenia
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Barbara Belletti
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Monica Schiappacassi
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| | - Gustavo Baldassarre
- Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy
| |
Collapse
|
8
|
Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrisi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A. Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. Tumori 2018; 98:33-8. [DOI: 10.1177/030089161209800104] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background Lapatinib in combination with capecitabine is feasible in patients with HER2-positive metastatic breast cancer pretreated with anthracyclines, taxanes and trastuzumab, but inferior results were reported in the global lapatinib expanded access program in comparison with the phase III registration trial. Methods and Study Design Women with HER2-positive metastatic breast carcinoma after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. The outcome of these patients was evaluated. From April 2007 to August 2010, 68 patients were treated overall. Results Median progression-free survival was 6 months (range, 1–29), and median overall survival was 26 months (range, 1–39). Eight (12%; 95% CI, 4–25) patients experienced a complete response. Partial response was observed in 22 patients (31%; 95% CI, 20–42), for an overall response rate of 43% (95% CI, 31–55). The treatment with lapatinib plus capecitabine was well tolerated, with grade 3–4 toxicity reported in few patients, and no treatment-related deaths were noted. Of note, no cardiac toxicity was reported in this highly pretreated group of patients or in the subgroup of 10 elderly patients. Conclusions Our data confirm that lapatinib plus capecitabine is an active regimen even in heavily pretreated patients with visceral and brain metastases and is feasible and active also in selected elderly patients.
Collapse
Affiliation(s)
- Diana Crivellari
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| | - Simon Spazzapan
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| | - Davide Lombardi
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| | - Loredana Militello
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
- Dept of Biomedical Sciences, University of Catania, Catania
| | - Elena Torrisi
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
- Dept of Biomedical Sciences, University of Catania, Catania
| | - Alessia E Russo
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
- Dept of Biomedical Sciences, University of Catania, Catania
| | - Roberto Sorio
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| | | | - Gianmaria Miolo
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| | - Paolo Carli
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| | - Andrea Veronesi
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN)
| |
Collapse
|
9
|
Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol 2018; 126:177-180. [DOI: 10.1016/j.radonc.2017.08.032] [Citation(s) in RCA: 85] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 08/14/2017] [Accepted: 08/20/2017] [Indexed: 12/15/2022]
|
10
|
Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae' DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo' M. Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. Front Immunol 2017; 8:1476. [PMID: 29163540 PMCID: PMC5681493 DOI: 10.3389/fimmu.2017.01476] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 10/20/2017] [Indexed: 12/15/2022] Open
Abstract
Local irradiation of cancer through radiotherapy can induce spontaneous regression of non-directly irradiated lesions, suggesting the involvement of systemic antitumor immune responses. In oligometastatic breast cancer (BC) patients, the use of stereotactic body radiotherapy (SBRT) favors the local control of treated lesions and may contribute to break local tolerance and release tumor-associated antigens (TAAs), improving host antitumor immunity. We performed a detailed immunomonitoring of BC patients undergoing SBRT to verify its ability to “switch on” the anti-tumor immunity both systemically, in peripheral blood, and locally, employing in vitro BC models. Twenty-one BC patients with ≤6 metastases were treated with 3 daily doses of 10 Gy with SBRT. Blood samples for immune profiling were collected before and after treatment. One month after treatment a third of patients displayed the boosting or even the de novo appearance of polyfunctional CD4+ and CD8+ T cell responses against known BC TAAs (survivin, mammaglobin-A, HER2), through intracellular staining in flow cytometry. Half of patients showed increased numbers of activated natural killer (NK) cells, measured with multispectral flow cytometry, immediately after the first dose of SBRT. Interestingly, high levels of activated NK cells at diagnosis correlated with a longer progression-free survival. BC in vitro models, treated with the same SBRT modality, showed enhanced expression of MHC class-I and class-II, major histocompatibility complex class I-related chain A/B, and Fas molecules, and increased release of pro-inflammatory cytokines, such as IL-1β and TNF-α. Consistently, we noticed enhanced production of perforin by CD4+ T cells when patients’ lymphocytes were cultured in the presence of irradiated BC cell line, compared to untreated targets. Besides immunogenic effects, SBRT also enhanced the percentages of circulating regulatory T cells, and increased indoleamine 2,3 dioxygenase and PD-L1 expression in BC in vitro models. These results suggest that SBRT may boost host antitumor immune responses also in an advanced disease setting such as oligometastatic BC, by inducing immunomodulating effects both locally and systemically. However, the concomitant induction of immunosuppressive pathways suggests that a combination with immunotherapy could further enhance the in situ vaccination ability of radiotherapy, possibly further improving the curative potential of SBRT in this subset of patients.
Collapse
Affiliation(s)
- Elena Muraro
- Immunopathology and Biomarker Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Carlo Furlan
- Department of Radiation Oncology, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Michele Avanzo
- Division of Medical Physics, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Debora Martorelli
- Immunopathology and Biomarker Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Elisa Comaro
- Immunopathology and Biomarker Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Aurora Rizzo
- Immunopathology and Biomarker Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Damiana A Fae'
- Immunopathology and Biomarker Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy
| | | | - Loredana Militello
- Department of Medical Oncology, CRO Aviano National Cancer Institute, Aviano, Italy
| | | | - Simon Spazzapan
- Department of Medical Oncology, CRO Aviano National Cancer Institute, Aviano, Italy
| | - Riccardo Dolcetti
- Immunopathology and Biomarker Unit, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy.,Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, QLD, Australia
| | - Marco Trovo'
- Department of Radiation Oncology, Azienda Sanitaria Universitaria Integrata of Udine, Udine, Italy
| |
Collapse
|
11
|
King CP, Militello L, Hart A, St Pierre CL, Leung E, Versaggi CL, Roberson N, Catlin J, Palmer AA, Richards JB, Meyer PJ. Cdh13 and AdipoQ gene knockout alter instrumental and Pavlovian drug conditioning. Genes Brain Behav 2017; 16:686-698. [PMID: 28387990 DOI: 10.1111/gbb.12382] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Revised: 03/30/2017] [Accepted: 04/02/2017] [Indexed: 12/11/2022]
Abstract
Genome-wide association studies in humans have suggested that variants of the cadherin-13 (CDH13) gene are associated with substance use disorder, subjective response to amphetamine, and attention deficit hyperactivity disorder. To examine the role of the Cdh13 and its peptide ligand adiponectin (AdipoQ) in addiction-related behaviors, we assessed Cdh13 knockout (KO) rats and AdipoQ KO mice using intravenous cocaine self-administration and conditioned place preference (CPP) paradigms. During intravenous cocaine self-administration, male Cdh13 heterozygous (+/-) and KO (-/-) rats showed increased cue-induced reinstatement compared with wild-type (WT) rats when presented with a cocaine-paired stimulus, whereas female Cdh13 rats showed no differences across genotype. Cdh13 -/- rats showed higher responding for a saccharin reinforcer and learned the choice reaction time (RT) task more slowly than WTs. However, we found no differences between Cdh13 -/- and +/+ rats in responding for sensory reinforcement, number of premature responses in the RT task, tendency to approach a Pavlovian food cue, CPP and locomotor activation to cocaine (10 or 20 mg/kg). In AdipoQ -/- mice, there was a significant increase in CPP to methamphetamine (1 mg/kg) but not to a range of d-amphetamine doses (0.5, 1, 2 and 4 mg/kg). Taken together, these data suggest that Cdh13 and AdipoQ regulate sensitivity to psychomotor stimulants and palatable rewards without producing major changes in other behaviors. In humans, these two genes may regulate sensitivity to natural and drug rewards, thus influencing susceptibility to the conditioned drug effects and relapse.
Collapse
Affiliation(s)
- C P King
- Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA
| | - L Militello
- Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, USA
| | - A Hart
- Department of Human Genetics, University of Chicago, Chicago, IL, USA.,Department of Immunology, Janssen R&D, Spring House, PA, USA
| | - C L St Pierre
- Department of Human Genetics, University of Chicago, Chicago, IL, USA.,Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
| | - E Leung
- Department of Human Genetics, University of Chicago, Chicago, IL, USA
| | - C L Versaggi
- Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA
| | - N Roberson
- Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA
| | - J Catlin
- Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA
| | - A A Palmer
- Department of Human Genetics, University of Chicago, Chicago, IL, USA.,Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.,Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA
| | - J B Richards
- Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, USA
| | - P J Meyer
- Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA
| |
Collapse
|
12
|
Trovo M, Furlan C, Berretta M, Militello L, Spazzapan S, Polesel J, Del Conte A, Arcangeli S, Fiorentino A, Franchin G. PO-0675: Radical radiotherapy in ologometastatic breast cancer patients. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31925-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med 2015; 13:204. [PMID: 26116238 PMCID: PMC4483222 DOI: 10.1186/s12967-015-0567-0] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Accepted: 06/09/2015] [Indexed: 12/22/2022] Open
Abstract
Background Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of these patients together with the immune-modulating activities of NC drugs suggest a potential contribution of host immunity in mediating clinical responses. We thus performed an extensive immunomonitoring in locally advanced BC patients undergoing NC to identify immunological correlates of pCR induction. Methods The immune profile of 40 HER2-positive and 38 HER2-negative BC patients was characterized at diagnosis and throughout NC (Paclitaxel and Trastuzumab, or Docetaxel and Epirubicin, respectively). The percentages of circulating immune cell subsets including T and B lymphocytes, Natural Killer (NK) cells, regulatory T cells, T helper 17 lymphocytes, were quantified by multiparametric flow cytometry. NK cells functional activity was evaluated through the analysis of NF-kB nuclear translocation by Multispectral flow cytometry, and with the in vitro monitoring of Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC). CD8+ T cell responses against six different tumor-associated antigens (TAA) were characterized by IFN-γ ELISPOT and IFN-γ/IL-2 DualSpot assays. Results After NC, HER2-positive patients showed a significant increase in the number of NK cells and regulatory T cells irrespective of the pathological response, whereas patients undergoing a pCR disclosed higher percentages of T helper 17 cells. Notably, a significant increase in the number of activated NK cells was observed only in HER2-positive patients achieving a pCR. Characterization of anti-tumor T cell responses highlighted sustained levels of CD8+ T cells specific for survivin and mammaglobin-A throughout NC in patients undergoing a pCR in both arms. Moreover, HER2-positive patients achieving a pCR were characterized by a multi-epitopic and polyfunctional anti-tumor T cell response, markedly reduced in case of partial response. Conclusions These results indicate that maintenance of functional T cell responses against selected antigens and improvement of NK cell proficiency during NC are probably critical requirements for pCR induction, especially in HER2-positive BC patients. Trail registration: Trial registration number: NCT02307227, registered on ClinicalTrials.gov (http://www.clinicaltrials.gov, November 26, 2014). Electronic supplementary material The online version of this article (doi:10.1186/s12967-015-0567-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- E Muraro
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - E Comaro
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - R Talamini
- Unit of Epidemiology and Biostatistics, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - E Turchet
- Scientific Direction, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - G Miolo
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - S Scalone
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - L Militello
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - D Lombardi
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - S Spazzapan
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - T Perin
- Department of Pathology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - S Massarut
- Division of Breast Surgical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - D Crivellari
- Department of Medical Oncology, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - Riccardo Dolcetti
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| | - D Martorelli
- Cancer Bio-Immunotherapy Unit, Department of Translational Research, CRO Aviano, IRCCS, National Cancer Institute, Via F. Gallini 2, 33081, Aviano, PN, Italy.
| |
Collapse
|
14
|
Carli P, Militello L, Miolo GM, Quitadamo D, Lombardi D, Torrisi E, Scalone S, Crivellari D, Spazzapan S. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience. Tumori 2015; 100:605-11. [PMID: 25688493 DOI: 10.1700/1778.19260] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown. METHODS AND STUDY DESIGN Women with HER2-positive metastatic breast carcinoma whose disease progressed after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. At progression on this combination, retreatment with trastuzumab combined with different cytotoxic agents was offered to most patients. The outcome of these patients was evaluated. RESULTS Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution. At progression, 43 (55%) were treated again with a trastuzumab-based regimen, mostly gemcitabine and vinorelbine. One complete response (CR) and 17 partial responses plus 4 prolonged stable periods longer than 6 months for a 51.1% overall clinical benefit were observed. No severe toxicities were encountered except one case of heart failure reported in a heavily antracycline-pretreated patient, who, however, recovered from this toxicity. CONCLUSIONS Even if our sample is a favorably selected population of HER2-positive patients responding to sequential targeted therapies, our data suggest that trastuzumab can be used again in association with a different cytotoxic agent in patients heavily pretreated with trastuzumab and after progression on lapatinib plus capecitabine, without any significant toxicity and with an encouraging clinical benefit rate, suggesting there is an opportunity to continue blockade of the HER2 receptor.
Collapse
|
15
|
|
16
|
Richards JB, Lloyd DR, Kuehlewind B, Militello L, Paredez M, Solberg Woods L, Palmer AA. Strong genetic influences on measures of behavioral-regulation among inbred rat strains. Genes Brain Behav 2013; 12:490-502. [PMID: 23710681 DOI: 10.1111/gbb.12050] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Revised: 04/22/2013] [Accepted: 05/14/2013] [Indexed: 11/27/2022]
Abstract
A fundamental challenge for any complex nervous system is to regulate behavior in response to environmental challenges. Three measures of behavioral-regulation were tested in a panel of eight inbred rat strains. These measures were: (1) sensation seeking as assessed by locomotor response to novelty and the sensory reinforcing effects of light onset, (2) attention and impulsivity, as measured by a choice reaction time task and (3) impulsivity as measured by a delay discounting task. Deficient behavioral-regulation has been linked to a number of psychopathologies, including ADHD, Schizophrenia, Autism, drug abuse and eating disorders. Eight inbred rat strains (August Copenhagen Irish, Brown Norway, Buffalo, Fischer 344, Wistar Kyoto, Spontaneous Hypertensive Rat, Lewis, Dahl Salt Sensitive) were tested. With n = 9 for each strain, we observed robust strain differences for all tasks; heritability was estimated between 0.43 and 0.66. Performance of the eight inbred rat strains on the choice reaction time task was compared to the performance of outbred Sprague Dawley (n = 28) and Heterogeneous strain rats (n = 48). The results indicate a strong genetic influence on complex tasks related to behavioral-regulation and indicate that some of the measures tap common genetically driven processes. Furthermore, our results establish the potential for future studies aimed at identifying specific alleles that influence variability for these traits. Identification of such alleles could contribute to our understanding of the molecular genetic basis of behavioral-regulation, which is of fundamental importance and likely contributes to multiple psychiatric disorders.
Collapse
Affiliation(s)
- J B Richards
- Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY 14203, USA.
| | | | | | | | | | | | | |
Collapse
|
17
|
Militello L, Carli P, Di Lauro V, Spazzapan S, Scalone S, Lombardi D, Tuzi A, Talamini R, Quitadamo D, Turchet E, Crivellari D. Bevacizumab as maintenance therapy (mBev) in metastatic breast cancer (MBC). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e22149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22149 Background: Preclinical models suggest that the anti-VEGF may improve the efficacy of anti-estrogen therapies in Hormonal Receptor positive (HR+) breast cancer, but there is lack of informations about the maintenance therapy with Bev (mBev) and Hormonal Therapy (HT). Methods: sixty-one pts with HER-2 negative MBC were treated, at our institution from 2007, with Bev+Taxanes (BT) as 1stline chemotherapy and with HT in HR+ pts as maintenance therapy. Primary endpoints were the evaluation of Progression Free Survival (PFS) and Overall Survival (OS). Secondary endpoint was the safety with HT in HR+ pts. Results: Hormonal status was positive in 52/61 (85%). Antracyclines were administered as adjuvant therapy in 26 pts (42%), antra+tax in 26 (42%) pts, no adjuvant therapy in 9 pts (14%). At the time of first relapse, median age was 50 y/o (range 33-72). First line HT was given to 12 pts. Metastatic sites were only bone in 20 pts (32%), visceral in 15 pts (25%), bone + visceral in 19 pts (31%), lymph nodes in 7 pts (11%). ECOG PS was 0 in 56 pts and 1 in 5. Median number of cycles of BT was 7 (1-14). All pts were evaluated for PFS and OS and 45 pts were evaluated for objective response: complete response (CR) was achieved in 5/45 pts (11%) (duration 12 months), partial response (PR) in 34/45 pts (75%) (duration 6-7 months), stable disease (SD) in 6/45 pts (14%) (6 months). After the assessment of the response, 34/61 pts received maintenance Bev (mBev); among this group, 24/34 pts with HR+ were also treated with HT until disease progression. The median number of cycles of mBev was 8 (1-42). Median PFS was 13.5 months (95%CI: 10.2-18.2) and median OS was 36 months (95%CI: 22-51). The BT regimen was well tolerated: 2 pts experienced cardiotoxicity with a reduction in left ventricular ejection fraction (LVEF); the most common side effects were hypertension (grade 1 in 11 pts e grade 2 in 16 pts), bleeding in 8 pts, proteinuria in 7 pts (grade 1 in 5 pts and grade 2 in 2 pts). Conclusions: Hormonalmaintenance and Bev can extend the overall benefit of therapy and it is well tolerated and associated with long-term clinical outcome. Our results are encouraging for prolonging Bev in association with HT as maintenance therapy until disease progression.
Collapse
Affiliation(s)
- Loredana Militello
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Paolo Carli
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | | | - Simon Spazzapan
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Simona Scalone
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Davide Lombardi
- Centro di Riferimento Oncologico - National Cancer Institute, Aviano, Italy
| | - Alessandro Tuzi
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Renato Talamini
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Daniela Quitadamo
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Elisa Turchet
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - Diana Crivellari
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| |
Collapse
|
18
|
Sonego M, Schiappacassi M, Lovisa S, Dall'Acqua A, Bagnoli M, Lovat F, Libra M, D'Andrea S, Canzonieri V, Militello L, Napoli M, Giorda G, Pivetta B, Mezzanzanica D, Barbareschi M, Valeri B, Canevari S, Colombatti A, Belletti B, Del Sal G, Baldassarre G. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med 2013; 5:707-22. [PMID: 23610071 PMCID: PMC3662314 DOI: 10.1002/emmm.201201504] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2012] [Revised: 02/18/2013] [Accepted: 02/20/2013] [Indexed: 01/07/2023] Open
Abstract
Stathmin is a p53-target gene, frequently overexpressed in late stages of human cancer progression. Type II High Grade Epithelial Ovarian Carcinomas (HG-EOC) represents the only clear exception to this observation. Here, we show that stathmin expression is necessary for the survival of HG-EOC cells carrying a p53 mutant (p53MUT) gene. At molecular level, stathmin favours the binding and the phosphorylation of p53MUT by DNA-PKCS, eventually modulating p53MUT stability and transcriptional activity. Inhibition of stathmin or DNA-PKCS impaired p53MUT–dependent transcription of several M phase regulators, resulting in M phase failure and EOC cell death, both in vitro and in vivo. In primary human EOC a strong correlation exists between stathmin, DNA-PKCS, p53MUT overexpression and its transcriptional targets, further strengthening the relevance of the new pathway here described. Overall our data support the hypothesis that the expression of stathmin and p53 could be useful for the identification of high risk patients that will benefit from a therapy specifically acting on mitotic cancer cells.
Collapse
Affiliation(s)
- Maura Sonego
- Division of Experimental Oncology 2, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Malaponte G, Polesel J, Candido S, Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello L, Mazzarino MC, Libra M, Signorelli SS. IL-6-174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine 2013; 62:64-9. [PMID: 23490413 DOI: 10.1016/j.cyto.2013.02.017] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Revised: 01/07/2013] [Accepted: 02/11/2013] [Indexed: 01/14/2023]
Abstract
BACKGROUND A growing body of evidence shows an increased risk of deep vein thrombosis (DVT) among cancer patients. Novel markers are needed to identify patients prone to develop DVT. The aim of the present study was to determine whether IL-6-174 G > C and MMP-9-1562 C > T polymorphisms may influence the development of DVT in cancer patients. METHODS Polymorphisms of IL-6 and MMP-9 were analyzed in 320 DNA samples from cancer patients (DVT+ and DVT-) and in 215 healthy donors. IL-6 and MMP-9 plasma levels were also measured by ELISA. RESULTS Distribution of -174 IL-6 genotype and -1562 MMP-9 were similar between healthy controls and DVT- cancer cases (OR = 0.98 and 1.04, respectively). Different results were obtained by compared healthy controls with DVT+ cancer patients. -174 IL-6 GG polymorphism was associated to DVT (OR = 2.07; 95% CI: 1.30-3.30), as well as -1562 MMP-9 CC polymorphism (OR = 2.60; 95% CI: 1.48-4.57). CONCLUSION The results of the present study support a model in which the GG and CC genotypes, respectively for IL-6-174 G > C and MMP-9-1562 C > T polymorphisms, are associated with a risk of DVT in cancer patients by inducing the release of IL-6 with subsequent increment of MMP-9. Overall, these findings may contribute to the management of DVT in cancer patients.
Collapse
Affiliation(s)
- Grazia Malaponte
- Laboratory of Immunopathology & Immunohistochemistry, Department of Bio-medical Sciences, Section of Pathology & Oncology, University of Catania, Catania, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrisi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. Tumori 2012. [PMID: 22495699 DOI: 10.1700/1053.11497] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS AND BACKGROUND Lapatinib in combination with capecitabine is feasible in patients with HER2-positive metastatic breast cancer pretreated with anthracyclines, taxanes and trastuzumab, but inferior results were reported in the global lapatinib expanded access program in comparison with the phase III registration trial. METHODS and study design. Women with HER2-positive metastatic breast carcinoma after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. The outcome of these patients was evaluated. From April 2007 to August 2010, 68 patients were treated overall. RESULTS Median progression-free survival was 6 months (range, 1-29), and median overall survival was 26 months (range, 1-39). Eight (12%; 95% CI, 4-25) patients experienced a complete response. Partial response was observed in 22 patients (31%; 95% CI, 20-42), for an overall response rate of 43% (95% CI, 31-55). The treatment with lapatinib plus capecitabine was well tolerated, with grade 3-4 toxicity reported in few patients, and no treatment-related deaths were noted. Of note, no cardiac toxicity was reported in this highly pretreated group of patients or in the subgroup of 10 elderly patients. CONCLUSIONS Our data confirm that lapatinib plus capecitabine is an active regimen even in heavily pretreated patients with visceral and brain metastases and is feasible and active also in selected elderly patients.
Collapse
Affiliation(s)
- Diana Crivellari
- National Cancer Institute, Division of Medical Oncology C, CRO, Aviano (PN), Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Velsor-Friedrich B, Militello L, Richards M. Effects of Coping Skills Training in Low-Income Urban African-American Adolescents with Asthma. J Allergy Clin Immunol 2012. [DOI: 10.1016/j.jaci.2011.12.479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Militello L, Carli P, Spazzapan S, Lestuzzi C, Miolo G, Scalone S, Veronesi A, Crivellari D. Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.282] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
282 Background: T is a mainstay in adjuvant therapy for HER2+ breast cancer (BC) patients (pts). Safety and efficacy of T in elderly patients are largely unknown. In HERA trial, NSABP B-31, NCCTG N9831 only 16% of pts were older than 60 years. Risk factors for T related cardiotoxicity are age (>50 y/o), hypertension, baseline LVEF (left ventricular ejection fraction <55%), previous antracycline therapy and BMI. Methods: Charts of pts >65 y/o with early HER2+ BC treated with T as adjuvant or neoadjuvant therapy at our institution were retrospectively reviewed. Primary endpoint was the evaluation of T cardiac toxicity and safety. Results: 22 elderly out of 172 pts (12%) were identified: 19 pts were treated only with surgery and adjuvant chemotherapy with concomitant or sequential T, 3 more pts also received neoadjuvant chemotherapy concomitant with T. According to Balducci’s criteria, fit, vulnerable and frail pts were 20, 2, 0 respectively. Median age was 69 y/o (range 65-76). Hormonal status was negative in 10/22 (45%). 21/22 were histologic grade 3. Median follow-up was 33 months. Baseline comorbidities were the following: hypertension (G2-3) in 17 pts, diabetes mellitus in 1, supra/infraventricular arrhythmia (G1-2) in 3 and 1 pts. Antracyclines were administered in 16 pts (liposomal-doxorubicin in 5 pts), a sequential taxane-regimen was used in 3 more pts. Neoadjuvant weekly Paclitaxel and concomitant T was used in 3 pts. Median basal LVEF was 65% (range 59-74%). 2 pts developed an asymptomatic 10% LVEF drop from baseline (left ventricular systolic dysfunction G1) during T treatment. Known cardiac risk factors were hypertension in 1 pt and previous antracycline based chemotherapy in both. They recovered within 9 months. One minor adverse event was atrial fibrillation (G2) during T treatment. Conclusions: T was well tolerated in elderly pts. More data are needed in order to understand the correlations between T related toxicity and cardiovascular risk factors. Long term safety of T treatment should verify the reversibility of cardiac T related toxicity on elderly pts.
Collapse
Affiliation(s)
- L. Militello
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - P. Carli
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - S. Spazzapan
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - C. Lestuzzi
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - G. Miolo
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - S. Scalone
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - A. Veronesi
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| | - D. Crivellari
- Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
| |
Collapse
|
23
|
Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol 2011; 38:1683-94. [PMID: 21455568 DOI: 10.3892/ijo.2011.984] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Accepted: 03/17/2011] [Indexed: 11/05/2022] Open
Abstract
LFB-R603 is a chimeric anti-CD20 mouse/human monoclonal antibody with a human IgG1 constant (Fc) region. In comparison to rituximab, LFB-R603 exhibits a high affinity to the Fcγ RIII (CD16) and a potent in vitro antibody-dependent cellular cytotoxicity (ADCC). We examined several experimental designs for the biological anti-tumor activity of LFB-R603 as well as its sensitizing activity to apoptosis in resistant non-Hodgin's B-cell lymphoma (B-NHL) in comparison to rituximab. Treatment of the B-NHL cell line Ramos with LFB-R603 was not toxic at the concentrations used and induced cell aggregation following culture at 24 and 48 h similarly to rituximab. Hence, we hypothesized that LFB-R603 may signal the tumor cells and modify intracellular survival/anti-apoptotic pathways. Treatment of Ramos cells with LFB-R603 inhibited the constitutively active NF-κB survival pathway, followed by significant potentiation of TRAIL-mediated apoptosis. We examined the underlying molecular mechanism by which the LFB-R603-mediated NF-κB inhibition results in the reversal of tumor cell resistance to TRAIL. We hypothesized that downstream gene products regulated by NF-κB that are involved in the resistance may be involved in LFB-R603-mediated sensitization. We found that LFB-R603 inhibited NF-κB activation and the anti-apoptotic factor Snail and induced the pro-apoptotic factor RKIP. The direct roles of Snail and RKIP modulation by LFB-R603 in the reversal of B-NHL resistance to TRAIL were examined by knocking down Snail and overexpressing RKIP in Ramos cells, respectively. Both approaches increased significantly the cell sensitivity to TRAIL apoptosis. In addition to changes observed in the expression levels of Snail and RKIP, Ramos cells treated with LFB-R603 induced the expression of PTEN along with inhibition of the PI3K-AKT activated pathway. PTEN silencing in Ramos cells pretreated with LFB-R603 and TRAIL inhibited TRAIL apoptosis; thus, demonstrating that PTEN induction by LFB-R603 has a direct role in tumor cell sensitization to TRAIL apoptosis. Several of the findings obtained in the experimental designs with LFB-R603 were superior to those obtained with rituximab. Overall, the findings demonstrate that LFB-R603 interferes with the dysregulated NF-κB/Snail/RKIP/PTEN/AKT resistance circuitry in B-NHL cells. Further, the findings suggest that LFB-R603 may sensitize tumor cells to various apoptotic stimuli including cytotoxic ligands such as TRAIL and chemotherapeutic drugs.
Collapse
Affiliation(s)
- Stavroula Baritaki
- Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-1747, USA
| | | | | | | | | | | |
Collapse
|
24
|
Amoroso A, Hafsi S, Militello L, Russo AE, Soua Z, Mazzarino MC, Stivala F, Libra M. Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci (Landmark Ed) 2011; 16:770-82. [PMID: 21196202 DOI: 10.2741/3719] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The addition of anti-CD20 monoclonal antibody (rituximab) to chemotherapy has significantly improved survival in B-cell lymphoma. However, a substantial number of patients relapse after treatment with rituximab. Understanding of anti-CD20 antibody molecular function may facilitate the development of pharmacologic strategies to overcome resistance. Cell death have been demonstrated to be caused by rituximab binding to CD20 throughout direct and indirect mechanisms. The direct mechanism comprises growth inhibition, induction of apoptosis and sensitization of cells to chemotherapy. While, the indirect mechanisms to Rituximab include complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). However, these mechanisms are still poorly understood. To shed light on this issue, we have analyzed the most significant results showing the role of Rituximab as a signal-inducing antibody and as a chemosensitizing agent through negative regulation of major survival pathways. Mechanisms of resistance to Rituximab are also discussed. Additionally, studies here reported show that, cellular targets are modified after treatment with Rituximab and may become useful for novel therapeutic strategies in the treatment of patients resistant to standard therapy.
Collapse
Affiliation(s)
- Alfredo Amoroso
- Department of Biomedical Sciences, University of Catania, Catania, Italy
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer 2010; 1:409-420. [PMID: 20827424 DOI: 10.1177/1947601910373795] [Citation(s) in RCA: 109] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Melanoma is a highly metastatic cancer, and there are no current therapeutic modalities to treat this deadly malignant disease once it has metastasized. Melanoma cancers exhibit B-RAF mutations in up to 70% of cases. B-RAF mutations are responsible, in large part, for the constitutive hyperactivation of survival/antiapoptotic pathways such as the MAPK, NF-κB, and PI3K/AKT. These hyperactivated pathways regulate the expression of genes targeting the initiation of the metastatic cascade, namely, the epithelial to mesenchymal transition (EMT). EMT is the result of the expression of mesenchymal gene products such as fibronectin, vimentin, and metalloproteinases and the invasion and inhibition of E-cadherin. The above pathways cross-talk and regulate each other's activities and functions. For instance, the NF-κB pathway directly regulates EMT through the transcription of gene products involved in EMT and indirectly through the transcriptional up-regulation of the metastasis inducer Snail. Snail, in turn, suppresses the expression of the metastasis suppressor gene product Raf kinase inhibitor protein RKIP (inhibits the MAPK and the NF-κB pathways) as well as PTEN (inhibits the PI3K/AKT pathway). The role of B-RAF mutations in melanoma and their direct role in the induction of EMT are not clear. This review discusses the hypothesis that B-RAF mutations are involved in the dysregulation of the NF-κB/Snail/RKIP/PTEN circuit and in both the induction of EMT and metastasis. The therapeutic implications of the dysregulation of the above circuit by B-RAF mutations are such that they offer novel targets for therapeutic interventions in the treatment of EMT and metastasis.
Collapse
Affiliation(s)
- Kimberly Lin
- Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA
| | | | | | | | | | | |
Collapse
|
26
|
Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009; 8:1367-72. [PMID: 19342874 DOI: 10.4161/cc.8.9.8314] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The Yin Yang 1 (YY1) transcription factor has a pivotal role in normal biological processes such as development, differentiation, replication and cell proliferation exerting its effects on a huge number of genes involved in these processes. Mechanisms of YY1 action are related to its ability to initiate, activate, or repress transcription depending upon the context in which it binds. The role of YY1 played in cancer has been recently explored. This article summarizes the most relevant studies focused on YY1 regulation and dwells on the way how its overexpression may affect the clinical behavior of several cancer types. Furthermore, the contribution of the upregulation of YY1 exerted in response to therapeutic-induced apoptosis is discussed.
Collapse
Affiliation(s)
- Giancarlo Castellano
- Unit of Molecular Therapies, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009; 8:1352-8. [PMID: 19305151 DOI: 10.4161/cc.8.9.8255] [Citation(s) in RCA: 147] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases that regulate signaling pathways involved in cell proliferation, adhesion, survival and motility. The PI3K pathway is considered to play an important role in tumorigenesis. Activating mutations of the p110alpha subunit of PI3K (PIK3CA) have been identified in a broad spectrum of tumors. Analyses of PIK3CA mutations reveals that they increase the PI3K signal, stimulate downstream Akt signaling, promote growth factor-independent growth and increase cell invasion and metastasis. In this review, we analyze the contribution of the PIK3CA mutations in cancer, and their possible implications for diagnosis and therapy.
Collapse
Affiliation(s)
- Giovanni Ligresti
- Department of Biomedical Sciences, University of Catania, Catania, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Ligresti G, Libra M, Militello L, Clementi S, Donia M, Imbesi R, Malaponte G, Cappellani A, McCubrey J, Stivala F. Breast cancer: Molecular basis and therapeutic strategies (Review). Mol Med Rep 2008. [DOI: 10.3892/mmr.1.4.451] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
29
|
Ligresti G, Libra M, Militello L, Clementi S, Donia M, Imbesi R, Malaponte G, Cappellani A, McCubrey JA, Stivala F. Breast cancer: Molecular basis and therapeutic strategies (Review). Mol Med Rep 2008; 1:451-458. [PMID: 21479431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Abstract
Breast cancer is the most common malignancy among women. It is frequently treated with chemotherapy and hormone therapy. More recently, however, 'targeted therapy' has emerged as an important approach to cancer therapy. Targeted therapy works by interfering with a specific molecular target, though inter-individual variability in drug response often causes treatment failure. Anticancer agents inhibit breast cancer progression by several different mechanisms. The Ras/Raf/MEK/ERK signal transduction pathway regulates cell cycle progression and apoptosis in diverse cell types. Alterations in this pathway are often associated with human cancer, including breast cancer. Understanding breast cancer biology is useful for the identification of appropriate anticancer drugs. This review describes the effect of gene alterations on breast cancer development. In addition, it shows how each anticancer drug used to treat breast cancer may block aberrant cell proliferation. Finally, the mechanisms of resistance to therapy are also discussed.
Collapse
Affiliation(s)
- Giovanni Ligresti
- Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
A study is presented utilizing the critical decision method to elicit knowledge from neonatal intensive care unit nurses regarding the assessment of infants at risk for necrotizing enterocolitis. Researchers were successful in eliciting knowledge not available in current nursing texts, including a framework for considering necrotizing enterocolitis and problem-solving strategies used by experienced nurses. Implications for nurse instruction and potential applications of this information are discussed.
Collapse
|
31
|
Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD, Berenberg JL. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 1992; 70:2547-51. [PMID: 1423183 DOI: 10.1002/1097-0142(19921115)70:10<2547::aid-cncr2820701025>3.0.co;2-f] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Malignant mesothelioma is a highly treatment-resistant neoplasm. This study represents an attempt to define an effective form of systemic therapy. METHODS Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks. Patients were either previously untreated with chemotherapy or had at most one prior systemic treatment. RESULTS Two patients, or 8% (95% confidence interval, 1-25%), achieved partial response, with response durations of 4 and 6 months. One additional patient met criteria for tumor size reduction but not duration criteria. Thirteen (50%) patients had stable disease of 4 months' median duration (range, 1-13 months). The median survival of the entire group was 6.5 months. The dose-limiting toxicity was granulocytopenia (11 patients, < or = 250/microliters). CONCLUSIONS Ifosfamide/mesna has modest activity in malignant mesothelioma. It could be tested using alternate dosage schedules and in combination with other agents in treating this highly resistant neoplasm.
Collapse
Affiliation(s)
- B L Zidar
- Allegheny Health, Education & Research Foundation, Pittsburgh, Pennsylvania
| | | | | | | | | | | | | |
Collapse
|
32
|
Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988; 6:223-6. [PMID: 3192388 DOI: 10.1007/bf00175403] [Citation(s) in RCA: 70] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2-21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued.
Collapse
|
33
|
Amato G, la Grutta V, D'Agostino V, Enia F, Militello L. Modifications in evoked activity in the visual cortex induced by the caudate nucleus. Arch Int Physiol Biochim 1971; 79:481-98. [PMID: 4107868 DOI: 10.3109/13813457109085332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
34
|
Amato G, La Grutta V, D'Agostino V, Enia F, Militello L. [Changes of the evoked activity of the visual cortex induced by the caudate nucleus in the cat]. Boll Soc Ital Biol Sper 1970; 46:951-4. [PMID: 5519766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
35
|
Militello L, Amato G, Rizzo A. [Effects of chemical stimulation of the caudate nucleus on spontaneous and evoked activity of the cerebral cortex in the cat]. Boll Soc Ital Biol Sper 1970; 46:957-60. [PMID: 5519768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
36
|
La Grutta V, Amato G, Militello L. The responsiveness of acoustic area after stimulation of the caudate nucleus. Experientia 1970; 26:259-60. [PMID: 5417484 DOI: 10.1007/bf01900081] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
37
|
La Grutta V, Amato G, Militello L. [Responsiveness of the specific auditory area of projection in relation to the inhibiting function of the caudate nucleus and centrum medianum]. Boll Soc Ital Biol Sper 1969; 45:1185-7. [PMID: 5384450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
38
|
Amato G, La Grutta V, Militello L, Enia F. Te function of the caudate nucleus in the control of some paroxystic activities in the neuraxis. Arch Int Physiol Biochim 1969; 77:465-84. [PMID: 4186364 DOI: 10.3109/13813456909069825] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
39
|
La Grutta V, Amato G, Militello L. The responsiveness of the auditory cortex as result of stimulation of the centrum medianum and caudate nucleus, in the cat. Arch Sci Biol (Bologna) 1969; 53:252-76. [PMID: 5406289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
40
|
Amato G, La Grutta V, Enia F, Militello L. [Effect of stimulation of the caudate nucleus on paroxysmal spinal activity induced by various drugs]. Boll Soc Ital Biol Sper 1969; 45:177-80. [PMID: 5346794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
41
|
La Grutta V, Militello L, Enia F, Amato G. [The action of the caudate nucleus on the cerebrocortical paroxysmal bioelectrical activity induced by some drugs]. Boll Soc Ital Biol Sper 1968; 44:1909-13. [PMID: 5735745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|